BlackRock’s Pasithea Therapeutics KTTA Stock Holding History

BlackRock’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-498	Closed	-$13K	–	5918
2022 Q1	$13K	Buy	498 +73	+17%	+$1.84K	﹤0.01%	5618
2021 Q4	$15K	Buy	+425	New	+$22.1K	﹤0.01%	5573

Other funds holding KTTA

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock's KTTA Position: Q2 2022 in Review

BlackRock sold out of Pasithea Therapeutics (KTTA) in Q2 2022, closing a stake of 498 shares — an estimated $13K sold.

BlackRock first reported a position in KTTA in Q4 2021 and held it in 2 quarters. The position peaked at $15K in Q4 2021. 10 funds tracked by Wall St. Rank hold KTTA as of Q2 2022.

BlackRock reported no remaining Pasithea Therapeutics position as of Q2 2022 after selling out during the quarter.
BlackRock sold 498 Pasithea Therapeutics shares in Q2 2022, an estimated $13K.
BlackRock first reported a position in Pasithea Therapeutics in Q4 2021 and held it in 2 quarters.
BlackRock's Pasithea Therapeutics position peaked at $15K in Q4 2021.
10 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.